1. Show article details.

    Bellerophon Therapeutics Announces Closing of $43.7 Million Public Offering of Common Stock and Concurrent Registered Direct Offering and Full Exercise of Option to Purchase Additional Shares

    GlobeNewswire – 9:47 AM ET 05/22/2020

    Bellerophon Therapeutics, Inc. (BLPH) today announced the closing of its previously announced public offering and concurrent registered direct offering for gross proceeds of approximately $43.7 million, which includes the full exercise of the underwriters’ option to purchase additional shares.

  2. Show article details.

    BRIEF-Theodore Wang Reports 13.1% Stake In Bellerophon Therapeutics

    Reuters – 7:46 AM ET 05/22/2020

    Bellerophon Therapeutics Inc (BLPH): * THEODORE WANG REPORTS 13.1% STAKE IN BELLEROPHON THERAPEUTICS AS OF MAY 21 - SEC FILING Source text for Eikon: [ID: https://bit.ly/3cVtmtK] Further company coverage:

  3. Show article details.

    BRIEF-Bellerophon Therapeutics Announces Pricing Of Public Offering Of Common Stock And Concurrent Registered Direct Offering

    Reuters – 7:58 AM ET 05/19/2020

    Bellerophon Therapeutics Inc (BLPH): * BELLEROPHON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND CONCURRENT REGISTERED DIRECT OFFERING. * BELLEROPHON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND CONCURRENT REGISTERED DIRECT OFFERING.

  4. Show article details.

    Bellerophon Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Registered Direct Offering

    GlobeNewswire – 7:00 AM ET 05/19/2020

    Bellerophon Therapeutics, Inc. (BLPH) today announced the pricing of offerings for an aggregate of 3,076,923 shares of its common stock at a public offering price of $13.00 per share. All securities in the offering are being sold by Bellerophon.

  5. Show article details.

    BRIEF-Bellerophon Therapeutics Announces Proposed Public Offering Of Common Stock

    Reuters – 4:35 PM ET 05/18/2020

    Bellerophon Therapeutics Inc (BLPH): * BELLEROPHON THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK. * BELLEROPHON THERAPEUTICS (BLPH) - EXPECTS TO USE PROCEEDS FROM OFFERING, TOGETHER WITH CASH AND CASH EQUIVALENTS, FOR FUNDING ITS ONGOING CLINICAL TRIALS Source text for Eikon: Further company coverage:

  6. Show article details.

    Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock

    GlobeNewswire – 4:03 PM ET 05/18/2020

    Bellerophon Therapeutics (BLPH), Inc.  today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. Bellerophon expects to use the net proceeds from this offering, together with its existing cash and cash equivalents, for funding its ongoing clinical trials, for working capital and general corporate purposes.

  7. Show article details.

    BRIEF-Bellerophon Reports Q1 Loss Per Share $1.08

    Reuters – 7:04 PM ET 05/11/2020

    Bellerophon Therapeutics Inc (BLPH): * BELLEROPHON PROVIDES CLINICAL PROGRAM UPDATE AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS. * Q1 LOSS PER SHARE $1.08 Source text for Eikon: Further company coverage:

  8. Show article details.

    Bellerophon Provides Clinical Program Update and Reports First Quarter 2020 Financial Results

    GlobeNewswire – 4:01 PM ET 05/11/2020

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2020.

  9. Show article details.

    BRIEF-Bellerophon Therapeutics Announces FDA Clears Initiation Of Phase 3 Study For Inopulse® Inhaled Nitric Oxide Therapy To Treat Covid-19

    Reuters – 8:41 AM ET 05/11/2020

    Bellerophon Therapeutics Inc (BLPH): * BELLEROPHON THERAPEUTICS ANNOUNCES FDA CLEARS INITIATION OF PHASE 3 STUDY FOR INOPULSE® INHALED NITRIC OXIDE THERAPY TO TREAT COVID-19. * BELLEROPHON - FDA ACCEPTED IND APPLICATION, ALLOWING CO TO INITIATE PHASE 3 STUDY OF INOPULSE INO THERAPY IN UP TO 500 PATIENTS INFECTED WITH COVID-19 Source text for Eikon: Further company coverage:

  10. Show article details.

    Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® Inhaled Nitric Oxide Therapy to Treat COVID-19

    GlobeNewswire – 8:30 AM ET 05/11/2020

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, today announced that the U.S. Food and Drug Administration accepted its Investigational New Drug application, allowing the Company to initiate a Phase 3 study of INOpulse® inhaled nitric oxide therapy in up to 500 patients infected with COVI...

  11. Show article details.

    Bellerophon Therapeutics to Participate in COVID-19 Panel at Maxim Group’s Infectious Disease Virtual Conference

    GlobeNewswire – 8:30 AM ET 05/04/2020

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer of Bellerophon, will participate in a COVID-19 panel at the upcoming Infectious Disease Virtual Conference presented by Maxim Group on Tuesday, May 5, 2020, at 3:45 PM ET.

  12. Show article details.

    BRIEF-Bellerophon Submits Investigational New Drug Application To Study Inhaled Nitric Oxide Therapy For COVID-19

    Reuters – 8:32 AM ET 04/08/2020

    Bellerophon Therapeutics Inc (BLPH): * BELLEROPHON THERAPEUTICS SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION TO STUDY INOPULSE® INHALED NITRIC OXIDE THERAPY FOR THE TREATMENT OF COVID-19. * BELLEROPHON - STUDY, CALLED PULSE-CVD19-001, WILL EVALUATE EFFICACY AND SAFETY OF INOPULSE IN PATIENTS WITH COVID-19 WHO REQUIRE SUPPLEMENTAL OXYGEN.

  13. Show article details.

    Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse® Inhaled Nitric Oxide Therapy for the Treatment of COVID-19

    GlobeNewswire – 8:30 AM ET 04/08/2020

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration to study the INOpulse® inhaled nitric oxide system for the treatment of patients infected with COVID-19.

  14. Show article details.

    Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results

    GlobeNewswire – 10:23 AM ET 04/06/2020

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter and year ended December 31, 2019.

  15. Show article details.

    Companies Seek New Methods to Fight Viral Infections

    PR Newswire – 9:00 AM ET 04/06/2020

    NEW YORK, April 6, 2020 Infectious diseases such as Ebola, Influenza, Zika, MERS and the recent pandemic that is still spreading, cause enormous loss of life and devastate economies around world. In the meantime, the current outbreak continues to force governments and many industries to try and come up with innovative solutions to slow down the spread of the virus.

  16. Show article details.

    BRIEF-Bellerophon Therapeutics Q4 Loss Per Share $0.89

    Reuters – 8:56 AM ET 04/06/2020

    Bellerophon Therapeutics Inc (BLPH): * Q4 LOSS PER SHARE $0.89 Source text: Further company coverage:

  17. Show article details.

    Bellerophon Announces Closing of $15.3 Million Registered Direct Offering of Common Stock

    GlobeNewswire – 1:06 PM ET 04/01/2020

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, closed its previously announced registered direct offering of 1,275,000 shares of its common stock at a purchase price of $12.00 per share for total gross proceeds of $15.3 million, before deducting placement agent fees and offering expenses.

  18. Show article details.

    BRIEF-Bellerophon Therapeutics Says Unable To Complete The Required Financial Statements And Audit Required For Filing Its Annual Report On Form 10-K

    Reuters – 6:11 PM ET 03/31/2020

    Bellerophon Therapeutics Inc (BLPH): * Bellerophon Therapeutics Inc (BLPH) - UNABLE TO COMPLETE THE REQUIRED FINANCIAL STATEMENTS AND AUDIT REQUIRED FOR FILING ITS ANNUAL REPORT ON FORM 10-K. * BELLEROPHON THERAPEUTICS (BLPH) - ANTICIPATED THAT FORM 10-K WILL BE FILED ON OR BEFORE THE 15TH CALENDAR DAY FOLLOWING THE PRESCRIBED DUE DATE Source: Further company coverage:

  19. Show article details.

    Bellerophon Therapeutics to Host Investor Call and Webcast Today on INOpulse® for the Treatment of COVID-19

    GlobeNewswire – 8:30 AM ET 03/31/2020

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, announced that it will host an investor conference call and webcast on the INOpulse® inhaled nitric oxide system for the treatment of COVID-19 at 1:00 PM EDT.

  20. Show article details.

    BRIEF-Bellerophon Therapeutics Announces First Patient Treated With Inopulse Inhaled Nitric Oxide Therapy For Covid-19

    Reuters – 10:25 AM ET 03/30/2020

    Bellerophon Therapeutics Inc (BLPH): * BELLEROPHON THERAPEUTICS ANNOUNCES FIRST PATIENT TREATED WITH INOPULSE® INHALED NITRIC OXIDE THERAPY FOR COVID-19 Source text for Eikon: Further company coverage:

Page:

Today's and Upcoming Events

  • Aug
    06

    BLPH to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    11

    BLPH announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.